Healio

FDA approves Firdapse, first treatment for Lambert-Eaton myasthenic syndrome

Please provide your email address to receive an email when new articles are posted on . The FDA has approved amifampridine tablets for the treatment of adult patients with Lambert-Eaton myasthenic ...
Healio

Study examines quality of life, survival outcomes in Lambert-Eaton myasthenic syndrome

Please provide your email address to receive an email when new articles are posted on . Patients with nontumor Lambert-Eaton myasthenic syndrome had survival rates comparable to the general population ...
Monthly Prescribing Reference

Dosing Update for Firdapse in Lambert-Eaton Myasthenic Syndrome

For adult and pediatric patients 6 years of age and older weighing at least 45kg, the maximum daily dosage has been increased from 80mg to 100mg. The Food and Drug Administration (FDA) has approved ...
Mena FN

Lambert Eaton Myasthenic Syndrome Market Positioned For Accelerated Development Through 2034, Delveinsight Finds Jacobus Pharmaceutical, Catalyst Pharmaceuticals

(MENAFN- GetNews) The Key Lambert Eaton Myasthenic Syndrome Companies in the market include - Jacobus Pharmaceutical, Catalyst Pharmaceuticals, and others. DelveInsight's “Lambert Eaton Myasthenic ...
Business Wire

Catalyst Announces Initiation of an Expanded Access Program to Provide Firdapse at No Cost to U.S. Patients with Lambert-Eaton Myasthenic Syndrome

CORAL GABLES, Fla.--(BUSINESS WIRE)--Catalyst Pharmaceutical Partners, Inc. announced today it has begun the process required to establish an expanded access program (EAP) to make available in the ...
ascopubs.org

Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS

Pre- and Post-Transplantation Risk Factors for Delirium Onset and Severity in Patients Undergoing Hematopoietic Stem-Cell Transplantation We derived a prediction score for SCLC in LEMS in a nationwide ...
Monthly Prescribing Reference

First-in-Class Drug Approved for Lambert-Eaton Myasthenic Syndrome

Firdapse was previously granted Orphan Drug designation and Breakthrough Therapy designation, as well as Priority Review by the FDA. The Food and Drug Administration (FDA) has approved Firdapse ...
Sterling Journal-Advocate

Myasthenia gravis and LEMS

This week we are going to discuss a topic that we had briefly touched on earlier, the neurologic autoimmune conditions: myasthenia gravis and Lambert Eaton Syndrome (LEMS). To review: Myasthenia ...

Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move?

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals ( CPRX +0.06%), exercised and immediately sold ...
Medscape

FDA OKs First Treatment for Lambert-Eaton Myasthenic Syndrome

The US Food and Drug Administration (FDA) has approved amifampridine (Firdapse, Catalyst Pharmaceuticals) 10-mg tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
The American Journal of Managed Care

FDA Approves First Treatment for Pediatric Lambert-Eaton Myasthenic Syndrome

The FDA has granted approval to the first treatment for children with Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. The drug, amifampridine (Ruzurgi), is approved for the ...